ArticleFrontiers in medicine2026
Real-world effectiveness and safety of tenofovir amibufenamide in treatment-naïve chronic hepatitis B: a 48-week retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tenofovir amibufenamide (TMF) is a newly recommended first-line nucleos(t)ide analogues for chronic hepatitis B (CHB) in China. However, real-world evidence on its safety and effectiveness are limited. This study aimed to evaluate the short-term virological efficacy, biochemical response, as well as safety profile of TMF over 48 weeks in a real-world cohort of CHB individuals. Methods: In this single-center retrospective cohort study, 129 treatment-naïve CHB patients were administered TMF at 25 mg daily. Clinical, virological, and biochemical parameters were gathered at baseline and at weeks 12, 24, and 48 for evaluation. The primary effectiveness endpoint was virological response (VR, HBV DNA <10 IU/mL) after 48 weeks of treatment. Secondary endpoints included VR at other timepoints, alanine aminotransferase (ALT) normalization, and changes in renal parameters and lipid levels. Results: At week 48, 72.9% (94/129) of patients achieved VR. Multivariate analysis identified lower baseline HBsAg levels, HBeAg negative status and non-cirrhotic status as independent predictors for achieving VR. The ALT normalization rate was 77.5% (100/129) at week 48. One patient achieved HBsAg seroclearance. Regarding safety, no adverse events linked to the medication were observed. There were no statistically significant alterations in serum phosphorus, estimated glomerular filtration rate, serum creatinine, or lipid levels (triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein) from baseline to week 48. Conclusion: In this single-arm observational cohort, TMF treatment achieved effective virological suppression and high rates of ALT normalization by week 48, with renal function and lipid levels remaining stable. Because the study lacked a comparator group, these findings should be regarded as observational. Comparative conclusions about the safety or superiority of TMF relative to tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) require dedicated head-to-head studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.